ENHANCING MOST-FAVORED-NATION PRICING: Today, President Donald J. Trump unveiled a pivotal agreement with AstraZeneca, a leading pharmaceutical company, aimed at aligning American drug prices with the lowest rates established by other advanced nations, known as the most-favored-nation (MFN) prices.
- This agreement will ensure that every Medicaid program across the nation has access to MFN drug prices for AstraZeneca medications, leading to substantial savings amounting to hundreds of millions of dollars and continuing President Trump’s commitment to fortifying assistance for those in greatest need.
- The deal protects American innovation by preventing foreign countries from exploiting price controls, stipulating that all newly developed innovative drugs from AstraZeneca will adhere to MFN pricing.
- AstraZeneca is mandated to reinvest additional revenues gained from foreign sales due to the President’s robust America First trade policies back into benefits for American patients.
- The agreement necessitates AstraZeneca to sell its medicines directly to American patients at steep discounts compared to the list prices.
PROVIDING LOWER COSTS: Today’s initiatives are set to deliver significant cost reductions to American patients and the overall healthcare system.
- 9 million Americans rely on AstraZeneca’s medications and will gain from the President’s successful efforts to decrease prices.
- The 25 million Americans affected by asthma, alongside the 16 million who endure chronic obstructive pulmonary disease (COPD)—one of the leading causes of death in the U.S.—stand to benefit from these price adjustments.
- BEVESPI AEROSPHERE, utilized for treating COPD, will be offered to patients who purchase directly at a discount of 654% compared to the deal price.
- BREZTRI AEROSPHERE, another inhaler indicated for COPD, will be accessible at a direct purchase discount of 98% off the deal price.
- AIRSUPRA, used for alleviating asthma symptoms, will be available at a significant discount of 96% off the deal price for patients buying directly.
COMMITTING TO AMERICAN PHARMACEUTICAL SUPPLY CHAINS: AstraZeneca has also made a pledge to invest $50 billion in manufacturing and research and development within the U.S. by 2030.
- A new plant is being established in Charlottesville, Virginia, which will manufacture advanced pharmaceutical ingredients to support chronic illness and oncology treatments.
- This facility will create 3,600 highly skilled job opportunities.
CONFRONTING GLOBAL FREELOADERS OF AMERICAN PHARMACEUTICAL INNOVATION: President Trump is taking decisive steps to recalibrate a system that allows pharmaceutical companies to sell drugs at lower prices in wealthier nations while charging significantly more in the U.S.
- Recent statistics indicate that Americans pay more than three times the price for brand-name medications compared to those in other OECD nations, even after accounting for manufacturer discounts provided domestically.
- Though the United States represents less than 5% of the global population, it generates approximately 75% of the global profits in the pharmaceutical sector, funded by American taxpayers.
- Companies in the drug manufacturing sector enjoy substantial research funding and significant spending from the U.S. Government on healthcare. However, instead of passing those savings to American consumers, these firms often price their products lower in foreign markets, recouping costs through higher prices in the U.S., thus forcing Americans to subsidize profits for both drug manufacturers and international health systems during both development and sale phases.
FULFILLING COMMITMENTS TO PRIORITIZE AMERICAN PATIENTS: President Trump is delivering on commitments made to American patients, which were deemed unattainable by the political establishment.
- On May 12, 2025, President Trump signed an Executive Order titled: “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” directing steps to align U.S. drug prices with those of similar developed nations.
- On July 31, 2025, President Trump communicated with major pharmaceutical manufacturers detailing required actions to align U.S. prescription drug prices with the lowest rates found in comparable developed countries.
- On September 30, 2025, a further agreement was made with Pfizer to ensure MFN pricing for American consumers.
- President Trump has shown relentless dedication to combat the inequitable and excessive costs American citizens face for prescription medications:
- President Trump stated: “In case after case, our citizens pay dramatically higher prices than other nations for the exact same pill, produced in the same factory, effectively funding socialism abroad with outrageous costs at home. We end up spending enormous sums to provide affordable medications to another country, and you can see pricing that is four to five times higher in some instances.”
